19th Conference of the Asian Pacific Association for the Study of the Liver
Poster Presentation(PP011)

 Hepatol Int (2009) 3:73

B.F. Wu¹
1 Hepatology & Gastroenterology Department, Dongguan Hospital of Tongji Medical College of Huazhong University Science & Technology, Dongguan, China

        Objective: To investigate the therapeutic effect of autologous HBsAg-loaded dendritic cells vaccine (anti-HBV DCs) on patients with chronic hepatitis B (CHB).
        Methods: Monocytes were isolated from peripheral blood of 11 patients with HBeAg-positive CHB and 5 patients with HBeAg-negative CHB by Ficoll-Hypaque density gradient centrifugating and cultured with plastic-adherence method. DCs were induced and proliferated from the monocytes with granulocyte-macrophage clony stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 7 days. After being incubated with HBsAg, DCs were injected to patients’vein for 4 times at one week’s interval. HBV markers, HBV-DNA levels, ALT and TBIL in the serum of patients were tested before and after treatment.
        Results: Results: The effective rate was 100% (16/16), and the cure rate was 6.25% (1/16). The HBsAg levels were (195.85±109.18) ng/ml and (69.98±78.65) ng/ml(t=5.14, P<0.001), the HBeAg levels were (3.08±1.76) Ncu/ml and (1.72±1.40) Ncu/ml (n=11, t=3.37, P=0.005), the HBeAb levels were (0.25±0.45) Ncu/ml and (0.82±0.74) Ncu/ml (n=11, t=2.34, P=0.041), the HBV-DNA levels were (8.41±9.86)×10⁷ copy/ml and (3.39±5.99)×10⁷ copy/ml (n=13, t=4.22, P=0.001), and the ALT levels were (60.73±20.14) U/L and (74.10±49.36) U/L (t=1.26, P=0.226) before and after treatment. The HBsAg of One patient with HBeAg-negative CHB were negative, and the HBeAb of another patient with HBeAg-positive CHB were positive after treatment.
        Conclusion: The autologous anti-HBV DCs induced in vitro can effectively suppress HBV replication, reduce and eliminate the virus antigen in sera, increase HBeAb level and promote HBeAg/HBeAb seroconversion on patients with CHB.

自体树突状细胞疫苗治疗慢性乙型肝炎的初步临床试验

第19届亚太肝脏研究会年会(香港)

海报展示(PP011) 

Hepatology International.2009,3:73

华中科技大学同济医学院附属东莞医院消化肝病中心  吴邦富

    目的  观察HBsAg致敏患者自体外周血单个核细胞(PBMC)来源的树突状细胞(DC)疫苗(简称抗HBV-DC)治疗慢性乙型肝炎(CHB)的临床效果。

    方法  11例HBeAg阳性CHB和5例HBeAg阴性CHB患者接受临床试验。取外周静脉血25毫升，用密度梯度离心及贴壁法获得单核细胞，以粒细胞-巨噬细胞集落刺激因子(GM-CSF)和白细胞介素4(IL-4)诱导扩增出DC，第5天给予30μg的HBsAg致敏DC。第7天收获DC静脉回输，每周1次，共4次。治疗前后检测HBV标志物定量、HBV-DNA定量及肝功能。

    结果  好转15例，治愈1例，有效率为100%，治愈率6.25%。治疗前后HBsAg为(195.85±109.18)ng/ml和(69.98±78.65)ng/ml(t＝5.14，P<0.001)，1例HBsAg转阴。HBeAg阳性CHB治疗前后HBeAg为(2.56±1.66)Ncu/ml和(1.60±1.46)Ncu/ml(t＝3.02，P=0.013)；HBeAb为(0.25±0.45)Ncu/ml和(0.82±0.74)Ncu/ml(t＝2.34，P=0.041)，1例HBeAb由阴转阳。HBV-DNA定量为(8.41±9.86)×10⁷copy/ml和(3.39±5.99)×10⁷copy/ml(t＝4.22，P=0.001)。ALT为(60.73±20.14)U/L 和(74.10±49.36)U/L(t＝1.26，P=0.226)。

    结论  抗HBV-DC静脉回输可有效地抑制CHB患者的病毒复制，降低并清除病毒抗原，促进HBeAb的产生，是一种安全、有效的治疗CHB患者的方法。